 Akebia Therapeutics Inc NASDAQ: AKBA shares are surging in Thursdays after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical. As a result of the termination of the agreements, Akebia. 